Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Psoriasis: Setting the Bar High for Therapeutic Advances
Description
The session focuses on recent advances in therapies for psoriasis and other inflammatory skin diseases, emphasizing a revolutionary trajectory that began over 20 years ago. It highlights various innovative treatments for psoriasis, such as the use of IL-36 blockers for pustular psoriasis, demonstrating remarkably effective results. The discussion includes the introduction of biosimilars and oral medications, alongside the efficacy and safety of established treatments like Ustekinumab and newer therapies like secukinumab, with emphasis on long-term data supporting their effectiveness. The session also explores the potential of novel oral drugs and ongoing clinical trials for psoriasis treatments, suggesting that new therapies are increasingly accessible. The consensus among presenters indicates a positive trajectory for psoriasis management, noting the importance of early treatment interventions. The event underscores the dynamic landscape of psoriasis therapies while expressing excitement for future advancements in the field.
View moreConclusions
- Spesolimab has shown significant efficacy in reducing the occurrence of Generalized Pustular Psoriasis (GPP) flares compared to placebo.
- The high-dose spesolimab group demonstrated a lower flare occurrence rate of 12.7%, whereas the placebo group had a 51.6% flare occurrence rate.
- Imsidolimab, another IL-36R antagonist, has exhibited promising safety and efficacy for treating GPP and may be a viable alternative for patients.
- Patients receiving biosimilars like CT-P43 showed comparable effectiveness to originator drugs, proving their viability as treatment options for moderate to severe psoriasis.
- New oral drugs, like SAR441566, targeted at TNF receptor 1, are under investigation and have demonstrated early positive results in managing psoriasis.
- Long-term data from therapies show sustained efficacy and low rate of adverse effects, enhancing their therapeutic benefit in managing psoriasis.
- Bachelez H, Choon S-E, Marrakchi S, Burden AD, Tsai T-F, Morita A, Navarini A-A, Zheng M, Xu J, Turki H, Anadkat MJ, Rajeswari S, Hua H, Vulcu SD, Hall D, Tetzlaff K, Thoma C, Lebwohl MG, for the Effisayil 1 Trial Investigators. Trial of Spesolimab for Generalized Pustular Psoriasis. N Engl J Med.